NovoCure Posts Record Q2 Revenue and Raises 2026 Outlook

Overview

• The company reported a record Q2 net revenue of $183.6 million and the stock climbed roughly 28% after management raised full-year 2026 revenue guidance to $710 million–$725 million.
• Adjusted EBITDA swung to a positive $10.8 million while GAAP net loss narrowed to about $15.7 million and the quarter ended with $440.6 million in cash and short-term investments.
• Global active patients on TTFields therapy rose about 18% to 5,128, with Optune Gio still the largest revenue driver and initial U.S. uptake of Optune Pax showing many prescribers have written only one prescription so far.
• Optune Pax received a CE Mark in Europe for locally advanced pancreatic cancer with Germany targeted as the first launch market and the company expects an FDA premarket approval decision for Optune Maia for brain metastases in Q4 2026.
• Management cut trial costs and reworked Phase III plans to preserve runway, but it still faces operational hurdles converting early prescribers into repeat users and securing hospital contracting to sustain growth.